Agenus | AGEN - Ordinary Share Capital


Agenus reported $35.32M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 35.32M 2.51M Dec/2025
Amgen USD 539M 1000K Dec/2025
AstraZeneca USD 1.55B 206K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 66.55M 102K Dec/2025
CSL USD 482.13M 93.87M Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Intrexon USD 0 0 Jun/2024
J&J USD 2.41B 1.74M Dec/2025
Jiangsu Hengrui CNY 6.64B 0 Dec/2025
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
MacroGenics USD 63.32M 60K Dec/2025
Merck EUR 434.78M 0 Dec/2025
Merck USD 2.49B 15.79M Sep/2025
Northwest Biotherapeutics USD 1.52B 1.52B Sep/2025
Novartis USD 1.91B 10.64M Dec/2025
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Veracyte USD 79.05M 377K Dec/2025